Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus concurrent chemoradiotherapy for postoperative lymph node recurrence of esophageal squamous cell carcinoma
ChiCTR1900024977Phase 4Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Soochow University
- Start
- Aug 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Third Affiliated Hospital of Soochow University. Primary endpoint: Progression-free survival time. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900024977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024977.